Literature DB >> 8678914

High density lipoproteins and coronary heart disease.

P J Barter1, K A Rye.   

Abstract

An inverse relationship between the concentration of high density lipoprotein (HDL) cholesterol and the development of coronary heart disease (CHD) is well established. It is unclear from the human studies whether this relationship reflects an ability of HDLs to protect against coronary disease or whether a low HDL in coronary patients is simply an epiphenomenon. Recent studies of transgenic mice, however, indicate that HDLs are directly antiatherogenic. The mechanism of the protection is unknown but may relate both to an involvement of HDLs in plasma cholesterol transport and to a range of non-lipid transport functions of HDLs. It is also unclear from human studies whether specific HDL subpopulations have differing abilities to protect against CHD, although such specificity is suggested from studies of transgenic mice. There is circumstantial evidence that elevating the concentration of HDL cholesterol in human subjects translates into a reduced coronary risk, although it should be stressed that there are still no reports of studies designed specifically to address this issue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8678914     DOI: 10.1016/0021-9150(95)05675-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  45 in total

1.  Cardiolipin is a normal component of human plasma lipoproteins.

Authors:  H Deguchi; J A Fernandez; T M Hackeng; C L Banka; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 2.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Biomarkers related to aging in human populations.

Authors:  Eileen Crimmins; Sarinnapha Vasunilashorn; Jung Ki Kim; Dawn Alley
Journal:  Adv Clin Chem       Date:  2008       Impact factor: 5.394

4.  Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II.

Authors:  M A Clay; D A Cehic; D H Pyle; K A Rye; P J Barter
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

5.  Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.

Authors:  John T Melchior; Scott E Street; Allison B Andraski; Jeremy D Furtado; Frank M Sacks; Rebecca L Shute; Emily I Greve; Debi K Swertfeger; Hailong Li; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

6.  Biodemography: new approaches to understanding trends and differences in population health and mortality.

Authors:  Eileen Crimmins; Jung Ki Kim; Sarinnapha Vasunilashorn
Journal:  Demography       Date:  2010

Review 7.  ACP Broad Sheet no 151: September 1997. Investigation of dyslipidaemias.

Authors:  A F Winder; W Richmond; D T Vallance
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

8.  Endothelial lipase-modified high-density lipoprotein exhibits diminished ability to mediate SR-BI (scavenger receptor B type I)-dependent free-cholesterol efflux.

Authors:  Martin Gauster; Olga V Oskolkova; Josef Innerlohinger; Otto Glatter; Gabriele Knipping; Sasa Frank
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

9.  Endurance training enhances ABCA1 expression in rat small intestine.

Authors:  Behzad Mehdi Khabazian; Abbass Ghanbari-Niaki; Ali reza Safarzadeh-Golpordesari; Mehdi Ebrahimi; Fatemeh Rahbarizadeh; Hossein Abednazari
Journal:  Eur J Appl Physiol       Date:  2009-07-24       Impact factor: 3.078

10.  Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.

Authors:  M Mastorikou; B Mackness; Y Liu; M Mackness
Journal:  Diabet Med       Date:  2008-09       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.